In partnership with
Letter from the editor
IL-17A and IL-17F blockade remarkably effective in psoriasis
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
IL-13 blocker tralokinumab effective in AD
Tape stripping - a painless way to distinguish AD and psoriasis?
IL-4/IL-13 blocker dupilumab effective in children with severe AD
Pembrolizumab leads to higher toxicity risk in obese melanoma patients
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Omalizumab for cancer-induced dermatoses
A new topical PDE-4 inhibitor effective in psoriasis
Biologic psoriasis treatment to lower cardiovascular risk?
Psoriasis therapy for children and pregnancies
How to manage cutaneous side effects of immunotherapy
Cannabinoids: a future role in dermatology?
Biologics in HS – a growing armamentarium
HS patients carry higher risk for systemic lupus erythematosus
Selective IL-23 blocker safe in elderly psoriasis patients
ECLIPSE trial: skin clearance independent of PsA status at baseline
Intranasal kappa-opioid agonist effective for intractable pruritus
Better compliance in AD skin care with novel emollient stick
Spironolactone safe for androgenetic alopecia in cancer survivors
Baricitinib beneficial in head and neck AD
Continuous terbinafine most effective for toenail onychomycosis
Top image: © damiangretka
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP